Executive previously served as chief financial officer of Moderna, Amgen, and 3M.
PacBio, a developer of sequencing solutions, announced the appointment of David Meline to its board of directors. Before joining PacBio, Meline most recently worked as chief financial officer of Moderna. Before joining Moderna, he spent time in the same role for both Amgen and 3M between 2008 and 2020.
"I am thrilled to join the PacBio Board at this pivotal stage," said Meline. "I've dedicated the latter part of my career to leading healthcare organizations that leveraged the power of genomics to develop some of the most groundbreaking therapies, so naturally, PacBio's mission resonated with me. I believe the industry has only scratched the surface on how genomics can transform human health and am eager to help guide the company as it executes this mission."
Reference: PacBio Announces Appointment of David Meline to Board of Directors. PR Newswire. October 16, 2023. Accessed October 16, 2023. https://www.prnewswire.com/news-releases/pacbio-announces-appointment-of-david-meline-to-board-of-directors-301957110.html
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.